Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Limited information is currently available on BMS-986277 (Aug 2018).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-986277||Limited information is currently available on BMS-986277, a putative oncolytic adenovirus expressing CD80 that is selective for epithelial cells (Mar 2020).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03363776||Phase Ib/II||BMS-986277 BMS-986277 + Nivolumab||An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers||Active, not recruiting|